Search Results
Mar 03, 2026, 09:00 ET REPROCELL、臨床用iPSCsのGMPマスターセルバンク製造を開始
本プラットフォームの一部として、 StemRNA Clinical iPSC Seed Clone「LLF-34-F3」は、米国のドナー材料に由来し、アクティブなFDAドラッグマスターファイル（DMF）によりサポートされています。このクローンは、FDAに準拠したクローズド・システム・プロセスを用いてGMP MCBに拡大されています。この市販のGMP iPSC MCBは現在商業利用が可能であり、臨床的に検証された出発物質をすぐに使用できます。欧州でのアライメントを必要とするスポンサーのために、REPROCELLはパートナーである
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
material.REPROCELL also offers options of StemRNA™ Clinical iPSC Seed Clones from different donor profiles.Dr. Chikafumi Yokoyama, CEO of REPROCELL Inc., commented:"By completing clinical iPSC workflow starting from donor screening, seed iPSC manufacturing, StemEdit gene editing, and GMP cell
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
material.REPROCELL also offers options of StemRNA™ Clinical iPSC Seed Clones from different donor profiles.Dr. Chikafumi Yokoyama, CEO of REPROCELL Inc., commented:"By completing clinical iPSC workflow starting from donor screening, seed iPSC manufacturing, StemEdit gene editing, and GMP cell
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET REPROCELL lanza la fabricación de bancos de células maestras GMP para iPSC clínicas
semilla StemRNA™ Clinical iPSC de diferentes perfiles de donantes.El doctor Chikafumi Yokoyama, consejero delegado de REPROCELL Inc., comentó:"Al completar el flujo de trabajo clínico de iPSC, desde la selección de donantes, la fabricación de semillas de iPSC, la edición genética StemEdit
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET REPROCELL startet GMP Master Cell Bank-Produktion für klinische iPSCs
wird der StemRNA Clinical iPSC Seed Clone - LLF-34-F3, der aus US-amerikanischem Spendermaterial stammt, durch eine aktive FDA Drug Master File (DMF) unterstützt. Dieser Klon wurde zu einem GMP-MCB erweitert, das FDA-konforme geschlossene Systemprozesse verwendet. Dieses GMP-iPSC-MCB ist jetzt für die kommerzielle
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET REPROCELL lance la fabrication de banques de cellules maîtresses conformes aux BPF pour les iPSC cliniques
semences cliniques iPSC StemRNA™ provenant de différents profils de donneurs.Le Dr Chikafumi Yokoyama, PDG de REPROCELL Inc., a commenté :« En complétant le flux de travail clinique des iPSC à partir de la sélection des donneurs, de la fabrication des semences iPSC, de l'édition génomique
More news about: REPROCELL USA
Mar 02, 2026, 09:10 ET XellSmart Receives Fourth Consecutive US FDA & China NMPA IND Clearance for MSA-P iPSC-derived Cell Therapy
off-the-shelf, allogeneic, universal, iPSC-derived, subtype-specific neuron progenitor cell therapy targeting Multiple System Atrophy- Parkinsonian Type (MSA-P). This joins the previous three consecutive FDA-NMPA registrational trial clearances for its universal iPSC-derived cell therapies targeting Parkinson's
More news about: XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd.
Feb 24, 2026, 09:00 ET Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer
clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions. By leveraging a proprietary, Nobel Prize-winning iPSC platform, Kenai is developing off-the-shelf, allogeneic neuron replacement and gene-modified cell therapies designed to be disease-modifying. Kenai's
More news about: Kenai Therapeutics/BIOCOM
Feb 23, 2026, 08:00 ET iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
pipeline of universal, iPSC-derived cell therapies for currently incurable diseases, led by its flagship program and several novel candidates:NouvNeu001 for Parkinson's disease – The world's first clinical-stage, allogeneic iPSC-derived, chemically induced
More news about: iRegene Therapeutics Co., Ltd.
Feb 18, 2026, 08:00 ET Klotho Neurosciences Receives Patent Claims in Australia for Composition and Use of Human Secreted Klotho Protein ("s-KL") Isoform of the Human Klotho Gene Sequence
encoding human the human s-KL protein for treating motor impairment. The claims also cover the use of neuronal cells and induced pluripotent stem cells (iPSC) containing the muscle-cell specific promoter and s-KL nucleic acid gene sequence encoding human the human s-KL protein and other cellular delivery
More news about: Klotho Neurosciences, Inc.
Feb 17, 2026, 08:05 ET JAX-NYSCF Collaborative and GSK Announce Collaboration to Advance Translational Models for Neurodegenerative Disease Research
discoveries —and accelerate therapies to patients—by bridging traditional disease models with next-generation patient-derived induced pluripotent stem cell (iPSC) models that more accurately capture the complexity of human biology at scale."Building More Predictive Models of Neurodegenerative DiseasesBy
More news about: The Jackson Laboratory-New York Stem Cell Foundation Collaborative
Feb 17, 2026, 08:00 ET GelMEDIX Completes $13 Million Seed Financing and Announces First Partnership
with late-stage GA by replacing damaged or dysfunctional RPE cells in the retina. The process involves injecting the liquid hydrogel containing healthy iPSC-derived RPE cells into the subretinal space and then activating it with white light to create a scaffold that mimics the natural environment of RPE
More news about: GelMEDIX
Feb 11, 2026, 08:00 ET Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accelerate
More news about: Evogene; Systasy; LMU University Hospital Munich
Jan 31, 2026, 08:28 ET India leads a 'Global Vision for Patient Safety' at Day 1 of Apollo Hospitals International Health Dialogue 2026
platform consisting of four specialized streams advancing safety, technology, clinical leadership and policy. International Patient Safety Conference (IPSC 2026) under this banner works towards safer and stronger systems of care. As one of Asia's leading platforms on patient safety, it brings together global
More news about: Apollo Hospitals Enterprise Limited
Jan 30, 2026, 09:30 ET I Peace Announces Successful Generation of Human iPS Cells from NKT Cells and Commences Their Availability
https://ipeace.com/en/), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it has successfully generated human induced pluripotent stem (iPS) cells from NKT cells and has begun offering
More news about: I Peace, Inc.
Jan 28, 2026, 23:09 ET リプロセル、AI設計ツールを活用した臨床遺伝子編集サービスでiPS細胞の新製品シリーズ「StemEdit」を発表
StemEditは、リプロセル独自の臨床用遺伝子編集技術と、即時利用可能な新しい遺伝子編集iPS細胞製品シリーズを包括するものです。本サービスは、リプロセルのStemRNA™ Clinical iPSC Seed Clonesと、OpenCRISPR-1™を利用したエンジニアリングワークフローを組み合わせたもので、GMPへの準拠、トレーサビリティ、規制当局への対応が可能なプラットフォームを初期段階から保証するものです。OpenCRISPR-1™は、de novo
More news about: REPROCELL USA
Jan 28, 2026, 09:00 ET REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
encompasses REPROCELL's proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL's StemRNA™ Clinical iPSC Seed Clones, with OpenCRISPR-1™ enabled engineering workflows, ensuring a GMP-aligned, traceable,
More news about: REPROCELL USA
Jan 28, 2026, 09:00 ET REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
encompasses REPROCELL's proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL's StemRNA™ Clinical iPSC Seed Clones, with OpenCRISPR-1™ enabled engineering workflows, ensuring a GMP-aligned, traceable,
More news about: REPROCELL USA
Jan 19, 2026, 08:00 ET FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions
the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson's disease (PD). This milestone makes NouvNeu001 the first allogeneic iPSC-derived cell therapy globally to hold both FDA Fast Track Designation (FTD) and RMAT designations, following the FTD granted in August 2025. These regulatory
More news about: iRegene Therapeutics Co., Ltd
Jan 14, 2026, 08:44 ET TheWell Bioscience Unveils RocketCell™ 3D iPSC Xeno-Free Complete Growth Kit: A Comprehensive Xeno-Free Ecosystem for Scalable iPSC Expansion
RocketCell™ product line, introducing two cutting-edge solutions for stem cell research: the RocketCell™ 3D iPSC Xeno-Free Complete Growth Kit and the RocketCell™ iPSC Xeno-Free Growth Medium. These products are engineered to resolve critical bottlenecks in 3D cell culture, including
More news about: TheWell Bioscience
Jan 13, 2026, 08:00 ET Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
TH41Human iPSC-Derived Oligodendrocytes Implicate Maturation Deficits in Neuropsychiatric Disease
More news about: Johnson & Johnson
Jan 12, 2026, 09:30 ET Trailhead Biosystems Expands Financing to $40 Million
conditions to generate iPSC-derived cells that closely match the molecular and functional properties of primary human cells.Advancing Product Development and Human-Relevant Cell ModelsThe additional financing will enable Trailhead to further develop its portfolio of iPSC-derived human cell
More news about: Trailhead Biosystems Inc
Jan 07, 2026, 08:50 ET Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
transition into the role of Chief Commercial Officer (CCO). These moves strengthen Aspen's late‑stage development and commercial readiness for its autologous iPSC‑derived cell therapy for Parkinson's disease.
More news about: Aspen Neuroscience, Inc.
Jan 06, 2026, 13:27 ET Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
MMP9-targeting ASOs capable of achieving robust knockdown of MMP9 mRNA and protein while attenuating inflammatory biomarkers implicated in ALS pathology in human iPSC-derived microglia. To enable translational pharmacology studies, the company developed a proprietary humanized MMP9 knock-in mouse model expressing
More news about: Aperture Therapeutics
Jan 06, 2026, 11:00 ET Novoron Bioscience Awarded $2.5 Million NIH/NIA SBIR Grant to Accelerate Alzheimer's Drug Discovery with Human Brain Organoids
Many Alzheimer's programs fail because traditional laboratory models cannot reflect the complexity of the human brain. Novoron's platform uses human iPSC-derived cortical organoids that capture realistic cell interactions and synaptic networks. This creates a more predictive setting for early drug discovery
More news about: Novoron Bioscience